Lappuse 1 no 309 rezultātiem
BACKGROUND
Medication overuse headache (MOH) is a disabling health problem. Convincing evidence attributes a pathophysiologic role to central sensitization. By recording somatosensory evoked potentials (SSEPs) in patients with MOH, we observed increased sensitization and deficient habituation to
OBJECTIVE
The aim of this study was to evaluate the angiotensin II receptor antagonist candesartan as prophylactic medication in patients with episodic cluster headache.
METHODS
This study comprised a prospective, placebo-controlled, double-blind, parallel-designed trial performed in seven centres
The renin-angiotensin system (RAS) is a major regulatory system controlling many different homeostatic mechanisms both within the brain and in the periphery. While it is primarily associated with blood pressure and salt/water regulation, increasing evidence points to the involvement of the RAS in
OBJECTIVE
To determine whether angiotensin II receptor antagonists prevent headaches.
METHODS
We systematically searched MEDLINE, EMBASE, the Cochrane Library, and International Pharmaceutical Abstracts for studies in which participants were randomly assigned to an angiotensin II receptor antagonist
Migraine constitutes 16% of primary headaches affecting 10-20% of general population according to International Headache Society. Till now nonsteroidalanti-inflammatory drugs (NSAIDS), opioids and triptans are the drugs being used for acute attack of migraine. Substances with proven efficacy for
BACKGROUND
Combination therapy with different classes of antihypertensive drugs often is needed to achieve controlled blood pressure (BP). The combination of an angiotensin II receptor antagonist (AIIA) and a calcium antagonist is a preferred option for reducing uncontrolled BP.
OBJECTIVE
The aim of
Wide use of angiotensin-converting enzyme (ACE) inhibitors in clinical settings is to a certain extent associated with a small number of side effects developing after taking the above medicines. The most prominent ill effects of ACE inhibitors include hypotension, acute renal impairement in those
Recent advances in genetic analysis of migraine headache are reviewed. Point mutations of P/Q -type Ca2+ channel alpha1 subunit(CACNA1A) gene and Na-K ATPase, alpha2 (ATP1A2) gene have been identified in the familial hemiplegic migraine (FHM-1 and FHM-2, respectively). Mutations in notch-3 gene
The aim of the work was to study hemodynamics and clinical symptoms before and after treatment of arterial hypertension (AH) and coronary heart disease (CHD) using angiotensin II receptor blockers and angiotensin converting enzyme inhibitors depending on the patients' sex. A total of 150 patients
Twenty patients with bladder cancer were treated with intra-arterial infusion chemotherapy using CDDP and ADM in combination with [Sar1, Ile8] angiotensin II. A catheter was introduced into internal iliac artery by Seldinger's technique, and 100 mg of CDDP, 50 mg of ADM and 1 mg of [Sar1, Ile8]
Migraine is a chronic disease with episodic attacks, which, when frequent or severe, can be associated with poor quality of life, increased health resource utilization, lost productivity, and significant disability. Preventive therapy can therefore have a significant beneficial clinical and economic
TCV-116 is a new, nonpeptide, angiotensin II type-1 receptor antagonist that acts as a specific inhibitor of the renin-angiotensin system. In this study, 36 healthy male volunteers were administered single and repeated oral doses of TCV-116 to investigate its effects on blood pressure and heart